G-418
Based on 68 publication(s) in Google Scholar
G-418 (Geneticin) is an aminoglycoside antibiotic with a structure similar to gentamicin. It is toxic to both eukaryotic and prokaryotic cells and works by interfering with protein synthesis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.42%
- CAS No.: 49863-47-0
- Formule: C20H40N4O10
- Masse moléculaire:496.55
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Antibacterial Compound Library
HY-L049
-
Antibiotics Library
HY-L067
-
Antiparasitic Compound library
HY-L082
-
Rare Diseases Drug Library
HY-L102
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
RNA Binding Bioactive Compound Library
HY-L248
-
Anti-Infection Compound Library
HY-L002
Publications Citing Use of MedChemExpress (MCE) G-418
More- Signal Transduct Target Ther. 2026 May 1;11(1):160. [Abstract]
- Cancer Cell. 2026 Jun 18.
- Nature. 2023 Jun;618(7966):862-870. [Abstract]
- Cell. 2026 Jun 25;189(13):4094-4106.e13. [Abstract]
- Cancer Commun (Lond). 2023 Jan;43(1):123-149. [Abstract]
- Cancer Res. 2023 Apr 4;83(7):1048-1061. [Abstract]
- Drug Resist Updat. 2026 Jan:84:101319. [Abstract]
- Protein Cell. 2025 Feb 18:pwaf014. [Abstract]
- Nat Commun. 2026 Mar 30. [Abstract]
- Nat Commun. 2026 Jan 20;17(1):614. [Abstract]
- Exp Mol Med. 2025 Nov;57(11):2686-2698. [Abstract]
- Redox Biol. 2025 Oct:86:103847. [Abstract]
- Mol Cell. 2023 Dec 7;83(23):4370-4385.e9. [Abstract]
- Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
- Adv Sci (Weinh). 2026 Jul;13(37):e24036. [Abstract]
- Adv Sci (Weinh). 2025 Nov 3:e13380. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(13):e2404961. [Abstract]
- Sci Adv. 2024 Aug 16;10(33):eado1533. [Abstract]
- Cell Death Differ. 2020 Jun;27(6):1981-1997. [Abstract]
- Cell Death Dis. 2026 Feb 26;17(1):241. [Abstract]
- Cell Mol Biol Lett. 2024 Feb 17;29(1):26. [Abstract]
- Cell Death Dis. 2020 Jun 4;11(6):420. [Abstract]
- Cell Death Dis. 2019 May 28;10(6):413. [Abstract]
- J Immunother Cancer. 2026 Feb 4;14(2):e012886. [Abstract]
- Adv Healthc Mater. 2025 Apr;14(10):e2404501. [Abstract]
- Acta Pharmacol Sin. 2025 Nov 1. [Abstract]
- Acta Pharmacol Sin. 2023 Oct;44(10):2103-2112. [Abstract]
- Int J Biol Macromol. 2025 Dec;333(Pt 1):148831. [Abstract]
- Int J Biol Macromol. 2025 Sep 17;329(Pt 1):147753. [Abstract]
- Clin Transl Med. 2026 Feb;16(2):e70603. [Abstract]
- J Genet Genomics. 2021 Feb 20;48(2):134-146. [Abstract]
- Cell Rep. 2022 Oct 25;41(4):111561. [Abstract]
- Cell Rep. 2021 Sep 21;36(12):109739. [Abstract]
- Cell Rep. 2021 Mar 30;34(13):108906. [Abstract]
- Cell Rep. 2020 Oct 20;33(3):108287. [Abstract]
- Transl Psychiatry. 2025 Apr 2;15(1):116. [Abstract]
- Int J Oncol. 2026 May;68(5):58. [Abstract]
- Emerg Microbes Infect. 2023 Dec;12(2):2261556. [Abstract]
- J Ethnopharmacol. 2025 Jul 24:351:120086. [Abstract]
- J Agric Food Chem. 2022 Apr 6;70(13):3989-3999. [Abstract]
- Biochem Pharmacol. 2026 Jan;243(Pt 2):117529. [Abstract]
- Biochem Pharmacol. 2025 Sep 13;242(Pt 2):117337. [Abstract]
- Cell Biosci. 2025 Apr 13;15(1):46. [Abstract]
- Life Sci. 2024 Jun 1:346:122626. [Abstract]
- Eur J Pharmacol. 2025 Feb 22:177418. [Abstract]
- Sci Rep. 2025 Jul 2;15(1):23651. [Abstract]
- J Cell Mol Med. 2023 Apr;27(7):962-975. [Abstract]
- Med Oncol. 2021 Nov 10;39(1):10. [Abstract]
- Biologics. 2025 Aug 12:19:443-462. [Abstract]
- BMC Complement Med Ther. 2024 Nov 16;24(1):400. [Abstract]
- FASEB J. 2023 Nov;37(11):e23195. [Abstract]
- J Biol Chem. 2023 May;299(5):104621. [Abstract]
- J Med Virol. 2026 Jan;98(1):e70777. [Abstract]
- Cancer Med. 2026 Apr;15(4):e71822. [Abstract]
- Am J Cancer Res. 2021 May 15;11(5):2062-2080. [Abstract]
- Hum Cell. 2022 Sep;35(5):1475-1486. [Abstract]
- Transl Cancer Res. 2023 Jan 30;12(1):150-162. [Abstract]
- Genes Genomics. 2026 Jun;48(6):935-949. [Abstract]
- Purdue University. 2025.
- Patent. US20240299557A1.
- Chemosphere. 2024 Oct:366:143350. [Abstract]
- Environ Toxicol. 2024 Sep;39(9):4447-4458. [Abstract]
- SSRN. 2024 Jun 19.
- Research Square Preprint. 2023 Jul 11.
- Research Square Print. 2023 Feb 21.
- Oxid Med Cell Longev. 2022 Jan 28;2022:8168988. [Abstract]
- Research Square Preprint. 2021 Nov.
- Research Square Preprint. 2020 Jun.
Voir tous les produits spécifiques à Isoform Parasite
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
Aminoglycoside |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf21 | IC50 |
2 μM
Compound: G418
|
Inhibition of ribosomal activity in Spodoptera frugiperda Sf21 cells assessed as inhibition of translation after 60 mins by fluorescence assay
Inhibition of ribosomal activity in Spodoptera frugiperda Sf21 cells assessed as inhibition of translation after 60 mins by fluorescence assay
|
[PMID: 20409719] |
G-418 (500 μg/mL, 12 days) was used to screen drug-resistant LNCaP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 49863-47-0
-
Appearance Solid
-
Masse moléculaire 496.55
-
Formule C20H40N4O10
-
Color White to off-white
-
SMILES
O[C@@H]([C@@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)N)([H])O[C@]2([H])[C@H](O)C)[C@H]([C@@H](C[C@@H]1N)N)O[C@](OC[C@](C)(O)[C@@H]3NC)([H])[C@@H]3O
-
Synonyms
Geneticin; Antibiotic G-418
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (68)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
BMAL1 regulates circadian rhythms via phase separation-mediated transcriptional hub formation. [Abstract]2026 May 1;11(1):160. PMID: 42062246 -
-
Nature
2023 Jun;618(7966):862-870. PMID: 37286607 -
Cell
Differential inhibition of Morbillivirus and Henipavirus polymerases by ERDRP-0519 and structure-guided inhibitor optimization. [Abstract]2026 Jun 25;189(13):4094-4106.e13. PMID: 42061399 -
Cancer Commun (Lond)
Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. [Abstract]2023 Jan;43(1):123-149. PMID: 36353796 -
Cancer Res
HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression. [Abstract]2023 Apr 4;83(7):1048-1061. PMID: 36745032 -
Drug Resist Updat
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]2026 Jan:84:101319. PMID: 41192279 -
Protein Cell
Cryo-EM structures of Nipah virus polymerase complex reveal highly varied interactions between L and P proteins among paramyxoviruses. [Abstract]2025 Feb 18:pwaf014. PMID: 39964914 -
Nat Commun
Epitranscriptomic RNA editing resolves Mus81 DNA repair tradeoffs in heat tolerance and meiosis. [Abstract]2026 Mar 30. PMID: 41912524 -
Nat Commun
The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. [Abstract]2026 Jan 20;17(1):614. PMID: 41559041 -
Exp Mol Med
RNA-binding protein HnRNPU regulates proliferation and ferroptosis in colon adenocarcinoma by stabilizing the mRNA of system xc. [Abstract]2025 Nov;57(11):2686-2698. PMID: 41310105 -
Redox Biol
Redox compartmentalization drives functional heterogeneity of mature insulin secretory vesicles in pancreatic β-cells. [Abstract]2025 Oct:86:103847. PMID: 40902318 -
Mol Cell
CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. [Abstract]2023 Dec 7;83(23):4370-4385.e9. PMID: 38016475 -
Theranostics
Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]2022 Jan 1;12(3):1187-1203. PMID: 35154482 -
Adv Sci (Weinh)
DTX3L Inhibits the EMT, Metastasis, and Stem-Like Features of Gastric Cancer Through Promoting GSK-3β Dependent SNAI1 Decay. [Abstract]2026 Jul;13(37):e24036. PMID: 41972409 -
Adv Sci (Weinh)
2025 Nov 3:e13380. PMID: 41178464 -
Adv Sci (Weinh)
Ribonuclease 1 Induces T-Cell Dysfunction and Impairs CD8+ T-Cell Cytotoxicity to Benefit Tumor Growth through Hijacking STAT1. [Abstract]2025 Apr;12(13):e2404961. PMID: 39932384 -
Sci Adv
Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22-mediated lipolysis circuit. [Abstract]2024 Aug 16;10(33):eado1533. PMID: 39151008 -
Cell Death Differ
ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. [Abstract]2020 Jun;27(6):1981-1997. PMID: 31831874 -
Cell Death Dis
Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A. [Abstract]2026 Feb 26;17(1):241. PMID: 41748538 -
Cell Mol Biol Lett
High-content image screening to identify chemical modulators for peroxisome and ferroptosis. [Abstract]2024 Feb 17;29(1):26. PMID: 38368371 -
Cell Death Dis
HOXA5 inhibits the proliferation and neoplasia of cervical cancer cells via downregulating the activity of the Wnt/β-catenin pathway and transactivating TP53. [Abstract]2020 Jun 4;11(6):420. PMID: 32499530 -
Cell Death Dis
Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. [Abstract]2019 May 28;10(6):413. PMID: 31138787 -
J Immunother Cancer
Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. [Abstract]2026 Feb 4;14(2):e012886. PMID: 41638869 -
Adv Healthc Mater
CircAars-Engineered ADSCs Facilitate Maxillofacial Bone Defects Repair Via Synergistic Capability of Osteogenic Differentiation, Macrophage Polarization and Angiogenesis. [Abstract]2025 Apr;14(10):e2404501. PMID: 40035523 -
Acta Pharmacol Sin
Galangin 3-methyl ether alleviates mouse hypertrophic cardiomyopathy via targeting HDAC2 and subsequently inactivating the PI3K-AKT signaling pathway. [Abstract]2025 Nov 1. PMID: 41176539 -
Acta Pharmacol Sin
Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1. [Abstract]2023 Oct;44(10):2103-2112. PMID: 37193754 -
Int J Biol Macromol
S100A4 regulates ferroptosis to suppress cell proliferation via the SLC7A11-GSH axis but facilitates Brucella infection in RAW264.7 macrophages. [Abstract]2025 Dec;333(Pt 1):148831. PMID: 41203174 -
Int J Biol Macromol
USP10-stabilized IGF2BP3 promotes tumor growth via m6A-modified SKP2 mRNA in non-small-cell lung cancer. [Abstract]2025 Sep 17;329(Pt 1):147753. PMID: 40972933 -
Clin Transl Med
2026 Feb;16(2):e70603. PMID: 41603084 -
J Genet Genomics
Leptin gene-targeted editing in ob/ob mouse adipose tissue based on the CRISPR/Cas9 system. [Abstract]2021 Feb 20;48(2):134-146. PMID: 33931338 -
Cell Rep
OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis. [Abstract]2022 Oct 25;41(4):111561. PMID: 36288705 -
Cell Rep
DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation. [Abstract]2021 Sep 21;36(12):109739. PMID: 34551297 -
Cell Rep
Sae2 and Rif2 regulate MRX endonuclease activity at DNA double-strand breaks in opposite manners. [Abstract]2021 Mar 30;34(13):108906. PMID: 33789097 -
Cell Rep
The 9-1-1 Complex Controls Mre11 Nuclease and Checkpoint Activation during Short-Range Resection of DNA Double-Strand Breaks. [Abstract]2020 Oct 20;33(3):108287. PMID: 33086066 -
Transl Psychiatry
A novel role of the antidepressant paroxetine in inhibiting neuronal Kv7/M channels to enhance neuronal excitability. [Abstract]2025 Apr 2;15(1):116. PMID: 40175331 -
Int J Oncol
2026 May;68(5):58. PMID: 41823537 -
Emerg Microbes Infect
Hepatitis B virus promotes its own replication by enhancing RAB5A-mediated dual activation of endosomal and autophagic vesicle pathways. [Abstract]2023 Dec;12(2):2261556. PMID: 37725090 -
J Ethnopharmacol
Danshen (Salvia miltiorrhiza) extract suppresses the growth of melanoma cells and induces autophagy by inhibiting the STAT3 pathway. [Abstract]2025 Jul 24:351:120086. PMID: 40466882 -
J Agric Food Chem
Alpinia hainanensis Rhizome Extract Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis: Active Ingredient Investigation and Evaluation. [Abstract]2022 Apr 6;70(13):3989-3999. PMID: 35321548 -
Biochem Pharmacol
Repurposing Lamivudine: A novel therapeutic strategy for ischemic stroke targeting the glycolytic enzyme Pgk1. [Abstract]2026 Jan;243(Pt 2):117529. PMID: 41213407 -
Biochem Pharmacol
piR-hsa-35410 promotes triple-negative breast cancer progression via enhancing PFKL mediated glycolysis. [Abstract]2025 Sep 13;242(Pt 2):117337. PMID: 40953645 -
Cell Biosci
The RBM39 degrader indisulam inhibits acute megakaryoblastic leukemia by altering the alternative splicing of ZMYND8. [Abstract]2025 Apr 13;15(1):46. PMID: 40223119 -
Life Sci
Geneticin ameliorates pulmonary fibrosis by attenuating the TGF-β/Smad via modulating AMPK/SIRT1 signaling. [Abstract]2024 Jun 1:346:122626. PMID: 38614295 -
Eur J Pharmacol
2025 Feb 22:177418. PMID: 39993702 -
Sci Rep
2025 Jul 2;15(1):23651. PMID: 40603466 -
J Cell Mol Med
4-octyl itaconate improves the viability of D66H cells by regulating the KEAP1-NRF2-GCLC/HO-1 pathway. [Abstract]2023 Apr;27(7):962-975. PMID: 36916028 -
Med Oncol
AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK signaling-independent manner in colorectal cancer cells. [Abstract]2021 Nov 10;39(1):10. PMID: 34761330 -
Biologics
2025 Aug 12:19:443-462. PMID: 40822676 -
BMC Complement Med Ther
Tongguanteng injection exerts anti-osteosarcoma effects through the ER stress-associated IRE1/CHOP pathway. [Abstract]2024 Nov 16;24(1):400. PMID: 39550552 -
FASEB J
RUNX1 promotes proliferation and migration in non-small cell lung cancer cell lines via the mTOR pathway. [Abstract]2023 Nov;37(11):e23195. PMID: 37801076 -
J Biol Chem
TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy. [Abstract]2023 May;299(5):104621. PMID: 36935008 -
J Med Virol
2026 Jan;98(1):e70777. PMID: 41480806 -
Cancer Med
2026 Apr;15(4):e71822. PMID: 41987392 -
Am J Cancer Res
Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells. [Abstract]2021 May 15;11(5):2062-2080. PMID: 34094669 -
Hum Cell
2022 Sep;35(5):1475-1486. PMID: 35792978 -
Transl Cancer Res
Expression and clinical significance of undifferentiated embryonic cell transcription factor 1 in breast cancer. [Abstract]2023 Jan 30;12(1):150-162. PMID: 36760370 -
Genes Genomics
2026 Jun;48(6):935-949. PMID: 41954878 -
-
-
Chemosphere
Toxicogenomic assessment of hydroxylated metabolites of PBDEs on cetaceans: An in vitro study. [Abstract]2024 Oct:366:143350. PMID: 39326706 -
Environ Toxicol
Long noncoding RNA VPS9D1-AS1 promotes the progression of endometrial cancer via regulation of the miR-187-3p/S100A4 axis. [Abstract]2024 Sep;39(9):4447-4458. PMID: 38953363 -
-
-
-
Oxid Med Cell Longev
HNF4A Regulates the Proliferation and Tumor Formation of Cervical Cancer Cells through the Wnt/ β-Catenin Pathway. [Abstract]2022 Jan 28;2022:8168988. PMID: 35132353 -
-
Solvant et solubilité
H2O : 100 mg/mL (201.39 mM; Need ultrasonic)
DMSO : 25 mg/mL (50.35 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.0139 mL | 10.0695 mL | 20.1390 mL | 50.3474 mL |
| 5 mM | 0.4028 mL | 2.0139 mL | 4.0278 mL | 10.0695 mL | |
| 10 mM | 0.2014 mL | 1.0069 mL | 2.0139 mL | 5.0347 mL | |
| 15 mM | 0.1343 mL | 0.6713 mL | 1.3426 mL | 3.3565 mL | |
| 20 mM | 0.1007 mL | 0.5035 mL | 1.0069 mL | 2.5174 mL | |
| 25 mM | 0.0806 mL | 0.4028 mL | 0.8056 mL | 2.0139 mL | |
| 30 mM | 0.0671 mL | 0.3356 mL | 0.6713 mL | 1.6782 mL | |
| 40 mM | 0.0503 mL | 0.2517 mL | 0.5035 mL | 1.2587 mL | |
| 50 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 1.0069 mL | |
| H2O | 60 mM | 0.0336 mL | 0.1678 mL | 0.3356 mL | 0.8391 mL |
| 80 mM | 0.0252 mL | 0.1259 mL | 0.2517 mL | 0.6293 mL | |
| 100 mM | 0.0201 mL | 0.1007 mL | 0.2014 mL | 0.5035 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
G-418 Related Classifications
HY-108718 Related Classifications
Powered by Bioz